SwedenBIO, the Swedish Life Science industry organization, in collaboration with Business Region Göteborg, Invest Skåne and Invest Stockholm is investigating the Swedish Life Science Investment Environment. The purpose of the study is to increase the understanding of how different types of funding affect companies’ ability to succeed with their investments and generate good returns for their owners. A guide to how the Swedish life science industry can continue to grow and develop!
We are looking for a wide selection of Life Science companies. Please participate if your company:
- is active within any field of life science e.g. biotech, medtech, pharma, diagnostics etc.
- is at any stage of development
Please leave 10-15 minutes to fill in questions and information about the company’s finance history. Your participation in this survey is done on an anonymous basis and forms an important part of the survey.
Background: Product development in Life Sciences is a very costly business that puts involved companies under constant pressure. Financing becomes a matter of life or death. During the past five years has the potential to obtain external financing increased in an environment driven by falling interest rates and equity investments in the sector, but we can not assume that the ”sweet spot” is made. It may be time to raise readiness for times with poorer access to risky capital while increasing the need for refinancing.
There is also reason to believe that the high element of public funding of this important Swedish industrial sector makes it more vulnerable to fluctuations in the stock market and investment cycles. By creating a clearer picture of the financial history of a large number of companies in this group, our chances of finding the capital structures that provide stable conditions will grow.
The survey will form the basis for a report on the financial strategies of early research company where we look at how the choice of financing, from a variety of soft funds to the share capital, may affect the companies’ chances to advance in the value chain.